Lasmiditan for the Acute Treatment of Migraine: Subgroup Analyses by Prior Response to Triptans

Cephalalgia - United States
doi 10.1177/0333102419889350
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Lasmiditan: New Drug for Acute Migraine

International Journal of Basic & Clinical Pharmacology
2019English

Assessing Cardiac Risk Prior to Use of Triptans

Headache
Neurology
2000English

Progress in Clinical Neurosciences a Systematic Review of the Use of Triptans in Acute Migraine

Canadian Journal of Neurological Sciences
MedicineNeurology
2001English

Adding Acute Treatments for Patients on Triptans: Results of the American Migraine Prevalence & Prevention (AMPP) Study

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2013English

Acute Migraine Treatment - Information for Patients

Canadian Journal of Neurological Sciences
MedicineNeurology
2013English

Prediction of Patient's Response to OnabotulinumtoxinA Treatment for Migraine

Heliyon
Multidisciplinary
2019English

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies

Headache
Neurology
2019English

Up to Date on the Use of Triptans for Child and Adolescent Migraine: State of the Art

Journal of Headache and Pain
MedicineNeurologyAnesthesiologyPain Medicine
2001English

Multimechanistic (Sumatriptan-Naproxen) Early Intervention for the Acute Treatment of Migraine

Neurology
Neurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy